Page 179 - 2021_12-Haematologica-web

Letters to the Editor
We conducted an observational, retrospective study including patients >18 years who were treated with dara- tumumab for ITP and/or warm AIHA (primary or second- ary) according to international criteria.13,14 The patients were identified through the French National Reference Center for Adult Immune Cytopenia network from November 2019 to November 2021. Any patient who
opposed data collection was not included. All patients were informed and gave consent to ‘off-label’ use of dara- tumumab. The initial treatment regimen was extrapolated from the one commonly used in myeloma4 (i.e., at least 4 daratumumab infusions at a dose of 16 mg/kg per week combined with oral dexamethasone 20 mg before each infusion). For ITP, complete response was defined as a
A
B
Figure 1. Autoimmune cytopenia evolution after daratumumab treatment. (A) Evolution of platelet counts in patients with immune thrombocytopenia after daratumumab. Patient #5 had acquired Glanzmann syndrome and red stars indicate hemorrhagic symptoms. (B) Evolution of hemoglobin levels in patients with warm autoimmune hemolytic anemia after daratumumab. Week 0 corresponds to the first daratumumab infusion (orange “D”). CS: corticosteroids, CYC: cyclophosphamide; IVIG: intravenous immunoglobulin, MMF: mycophenolate mofetil, RBC: red blood cell transfusion, SPL: splenectomy.
haematologica | 2021; 106(12)
3199